{"result": {"id": "35c6e91d-6bf1-4714-bc2b-56d7f1b6290c", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>SACUBITRIL/VALSARTAN<|>ORGANIZATION<|>Sacubitril/valsartan is a medication studied for its efficacy in treating hypertension and heart failure)\n##\n(\"entity\"<|>AMLODIPINE<|>ORGANIZATION<|>Amlodipine is a calcium channel blocker used in hypertension treatment, often studied in combination with other drugs)\n##\n(\"entity\"<|>ALISKIREN<|>ORGANIZATION<|>Aliskiren is a direct renin inhibitor investigated for hypertension treatment in various clinical trials)\n##\n(\"entity\"<|>LOSARTAN<|>ORGANIZATION<|>Losartan is an angiotensin receptor blocker studied in combination with other antihypertensive agents)\n##\n(\"entity\"<|>SPIRONOLACTONE<|>ORGANIZATION<|>Spironolactone is a mineralocorticoid receptor antagonist used in drug-resistant hypertension treatment)\n##\n(\"entity\"<|>FINERENONE<|>ORGANIZATION<|>Finerenone is a selective mineralocorticoid receptor antagonist with antifibrotic activity)\n##\n(\"entity\"<|>ACCELERATE TRIAL<|>EVENT<|>A randomized trial investigating aliskiren and amlodipine combination as initial hypertension treatment)\n##\n(\"entity\"<|>ASTRONAUT TRIAL<|>EVENT<|>A randomized trial evaluating aliskiren's effect on mortality and heart failure readmissions)\n##\n(\"entity\"<|>PATHWAY-2 TRIAL<|>EVENT<|>A randomized trial comparing spironolactone with other treatments for resistant hypertension)\n##\n(\"relationship\"<|>SACUBITRIL/VALSARTAN<|>AMLODIPINE<|>Studied in combination for treating systolic hypertension in Asian patients<|>7)\n##\n(\"relationship\"<|>ALISKIREN<|>AMLODIPINE<|>Investigated as combination therapy in the ACCELERATE trial<|>8)\n##\n(\"relationship\"<|>ALISKIREN<|>LOSARTAN<|>Studied in combination for type 2 diabetes and nephropathy<|>7)\n##\n(\"relationship\"<|>SPIRONOLACTONE<|>FINERENONE<|>Both are mineralocorticoid receptor antagonists studied for hypertension treatment<|>6)\n##\n(\"relationship\"<|>ALISKIREN<|>ASTRONAUT TRIAL<|>Aliskiren was the investigational drug in this heart failure outcomes trial<|>9)\n##\n(\"relationship\"<|>SPIRONOLACTONE<|>PATHWAY-2 TRIAL<|>Spironolactone was the primary intervention in this resistant hypertension study<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559055, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 612, "prompt_tokens": 6879, "total_tokens": 7491, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 4992}, "prompt_cache_hit_tokens": 4992, "prompt_cache_miss_tokens": 1887}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: on blood pressure in patients with hypertension:  a meta-analysis of randomized controlled trials[J].  Cardiology,  2020,145(9) :589-598.\n[277]  WangJG, YukisadaK, SibuloAJr, etal. Efficacyandsafetyof sacubitril/valsartan(LCZ696) add-ontoamlodipineinAsianpa- tients with systolic hypertension uncontrolled with amlodipine\n\n\n\nmonotherapy[J]. J Hypertens,2017,35(4) :877-885.\n[278]  LiW , Gong M, Yu Q, et al.  Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hyperten- sion[J]. J Clin Hypertens(Greenwich) ,2022,24(4) :449-456.\n[279] Jackson AM, JhundPS, AnandIS, etal. Sacubitril-valsartanas a treatmentforapparentresistanthypertension inpatients with heartfailure and preserved ejection fraction[J]. Eur Heart J,  2021,42(36) :3741-3752.\n[280]  中国医疗保健国际交流促进会高血压分会 , 中国医师协会心血  管分会 , 中国高血压联盟 ,等.  沙库巴曲缬沙坦在高血压患者临  床应用的中国专家建议[J]. 中华高血压杂志 , 2021, 29(2) : 108- 114.\n[281]《 α受体阻滞剂降压治疗中国专家共识》专家委员会. α受体阻滞 剂降压治疗中国专家共识[J]. 中华高血压杂志 , 2022, 30(5) : 409-416\n[282]  Brown MJ, McInnes GT, PapstCC, et al.  Aliskiren and the calcium channel blocker amlodipine combination as an initial treatmentstrategy for hypertension control (ACCELERATE) :  a randomised, parallel-group trial[J] Lancet, 2011, 377(9762) :  312-320.\n[283]  DuprezDA, MungerMA, BothaJ, etal. Aliskirenforgeriatric lowering of systolic hypertension: a randomized controlled trial [J]. J Hum Hypertens,2010,24(9) :600-608.\n[284]  Parving HH, Persson F, Lewis JB, et al.  Aliskiren combined withlosartan in type2 diabetes and nephropathy[J]. N EnglJ Med,2008,358(23) :2433-2446.\n[285]  Solomon SD, Appelbaum E, ManningWJ, etal.  Effectofthe directrenin inhibitoraliskiren, the angiotensin receptorblocker losartan, orbothonleftventricularmassinpatientswithhyper- tension and left ventricular hypertrophy[J]. Circulation, 2009,  119(4) :530-537.\n[286]  GheorghiadeM, B?hm M, GreeneSJ, etal. Effectofaliskiren on postdischargemortality and heartfailurereadmissionsamong patients hospitalized for heart failure: the ASTRONAUT ran- domized trial[J]. JAMA,2013,309(11) :1125-1135.\n[287]  Parving HH, BrennerBM, McMurrayJJ, etal. Cardiorenalend points in a trial of aliskiren for type 2 diabetes[J]. N EnglJ Med,2012,367(23) :2204-2213.\n[288]  Ferrario CM,  Schiffrin EL.  Role of mineralocorticoid receptor antagonistsin cardiovasculardisease[J]. CircRes,2015,116(1) :  206-213.\n[289]  苏定冯 ,陈丰原.  心血管药理学[M]. 4版. 北京 :人民卫生出版 社 ,2011:317-334.\n[290]  GruneJ, BeyhoffN, SmeirE, etal. Selectivemineralocorticoid receptorcofactormodulation as molecularbasis for finerenone's antifibroticactivity[J]. Hypertension,2018,71(4) :599-608.\n[291]  Gomez-SanchezEP.  Third-generation mineralocorticoid receptor antagonists: whydo weneed afourth[J]. J CardiovascPharma- col,2016,67(1) :26-38.\n[292]  Williams B, MacDonald TM, MorantS, et al.  Spironolactone versusplacebo, bisoprolol, and doxazosinto determinetheopti- maltreatmentfordrug-resistanthypertension(PATHWAY-2) :  a randomised, double-blind,  crossover trial[J]. Lancet, 2015,  386(10008) :2059-2068.\n[\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CARDIOLOGY<|>ORGANIZATION<|>Cardiology is a journal that published a meta-analysis of randomized controlled trials on blood pressure in patients with hypertension in 2020)\n##\n(\"entity\"<|>WANGJG<|>PERSON<|>WangJG is a researcher who contributed to a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension)\n##\n(\"entity\"<|>YUKISADAK<|>PERSON<|>YukisadaK is a researcher who contributed to a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension)\n##\n(\"entity\"<|>SIBULOAJR<|>PERSON<|>SibuloAJr is a researcher who contributed to a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension)\n##\n(\"entity\"<|>J HYPERTENS<|>ORGANIZATION<|>J Hypertens is a journal that published a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension in 2017)\n##\n(\"entity\"<|>LIW<|>PERSON<|>LiW is a researcher who contributed to a study on the efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension)\n##\n(\"entity\"<|>GONG M<|>PERSON<|>Gong M is a researcher who contributed to a study on the efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension)\n##\n(\"entity\"<|>YU Q<|>PERSON<|>Yu Q is a researcher who contributed to a study on the efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension)\n##\n(\"entity\"<|>J CLIN HYPERTENS<|>ORGANIZATION<|>J Clin Hypertens is a journal that published a study on the efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension in 2022)\n##\n(\"entity\"<|>JACKSON AM<|>PERSON<|>Jackson AM is a researcher who contributed to a study on sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction)\n##\n(\"entity\"<|>JHUNDPS<|>PERSON<|>JhundPS is a researcher who contributed to a study on sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction)\n##\n(\"entity\"<|>ANANDIS<|>PERSON<|>AnandIS is a researcher who contributed to a study on sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction)\n##\n(\"entity\"<|>EUR HEART J<|>ORGANIZATION<|>Eur Heart J is a journal that published a study on sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction in 2021)\n##\n(\"entity\"<|>中国医疗保健国际交流促进会高血压分会<|>ORGANIZATION<|>中国医疗保健国际交流促进会高血压分会 is an organization that contributed to a Chinese expert recommendation on the clinical application of sacubitril/valsartan in hypertensive patients)\n##\n(\"entity\"<|>中国医师协会心血管分会<|>ORGANIZATION<|>中国医师协会心血管分会 is an organization that contributed to a Chinese expert recommendation on the clinical application of sacubitril/valsartan in hypertensive patients)\n##\n(\"entity\"<|>中国高血压联盟<|>ORGANIZATION<|>中国高血压联盟 is an organization that contributed to a Chinese expert recommendation on the clinical application of sacubitril/valsartan in hypertensive patients)\n##\n(\"entity\"<|>中华高血压杂志<|>ORGANIZATION<|>中华高血压杂志 is a journal that published a Chinese expert recommendation on the clinical application of sacubitril/valsartan in hypertensive patients in 2021)\n##\n(\"entity\"<|>《 α受体阻滞剂降压治疗中国专家共识》专家委员会<|>ORGANIZATION<|>《 α受体阻滞剂降压治疗中国专家共识》专家委员会 is an organization that contributed to a Chinese expert consensus on the treatment of hypertension with α-blockers)\n##\n(\"entity\"<|>BROWN MJ<|>PERSON<|>Brown MJ is a researcher who contributed to a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control)\n##\n(\"entity\"<|>MCINNES GT<|>PERSON<|>McInnes GT is a researcher who contributed to a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control)\n##\n(\"entity\"<|>PAPSTCC<|>PERSON<|>PapstCC is a researcher who contributed to a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control)\n##\n(\"entity\"<|>LANCET<|>ORGANIZATION<|>Lancet is a journal that published a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control in 2011)\n##\n(\"entity\"<|>DUPREZDA<|>PERSON<|>DuprezDA is a researcher who contributed to a study on aliskiren for geriatric lowering of systolic hypertension)\n##\n(\"entity\"<|>MUNGERMA<|>PERSON<|>MungerMA is a researcher who contributed to a study on aliskiren for geriatric lowering of systolic hypertension)\n##\n(\"entity\"<|>BOTHAJ<|>PERSON<|>BothaJ is a researcher who contributed to a study on aliskiren for geriatric lowering of systolic hypertension)\n##\n(\"entity\"<|>J HUM HYPERTENS<|>ORGANIZATION<|>J Hum Hypertens is a journal that published a study on aliskiren for geriatric lowering of systolic hypertension in 2010)\n##\n(\"entity\"<|>PARVING HH<|>PERSON<|>Parving HH is a researcher who contributed to a study on aliskiren combined with losartan in type 2 diabetes and nephropathy)\n##\n(\"entity\"<|>PERSSON F<|>PERSON<|>Persson F is a researcher who contributed to a study on aliskiren combined with losartan in type 2 diabetes and nephropathy)\n##\n(\"entity\"<|>LEWIS JB<|>PERSON<|>Lewis JB is a researcher who contributed to a study on aliskiren combined with losartan in type 2 diabetes and nephropathy)\n##\n(\"entity\"<|>N ENGLJ MED<|>ORGANIZATION<|>N EnglJ Med is a journal that published a study on aliskiren combined with losartan in type 2 diabetes and nephropathy in 2008)\n##\n(\"entity\"<|>SOLOMON SD<|>PERSON<|>Solomon SD is a researcher who contributed to a study on the effect of aliskiren, losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy)\n##\n(\"entity\"<|>APPELBAUM E<|>PERSON<|>Appelbaum E is a researcher who contributed to a study on the effect of aliskiren, losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy)\n##\n(\"entity\"<|>MANNINGWJ<|>PERSON<|>ManningWJ is a researcher who contributed to a study on the effect of aliskiren, losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy)\n##\n(\"entity\"<|>CIRCULATION<|>ORGANIZATION<|>Circulation is a journal that published a study on the effect of aliskiren, losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy in 2009)\n##\n(\"entity\"<|>GHEORGHIADEM<|>PERSON<|>GheorghiadeM is a researcher who contributed to a study on the effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure)\n##\n(\"entity\"<|>B?HM M<|>PERSON<|>B?hm M is a researcher who contributed to a study on the effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure)\n##\n(\"entity\"<|>GREENSJ<|>PERSON<|>GreeneSJ is a researcher who contributed to a study on the effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure)\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>JAMA is a journal that published a study on the effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure in 2013)\n##\n(\"entity\"<|>BRENNERBM<|>PERSON<|>BrennerBM is a researcher who contributed to a study on cardiorenal endpoints in a trial of aliskiren for type 2 diabetes)\n##\n(\"entity\"<|>MCMURRAYJJ<|>PERSON<|>McMurrayJJ is a researcher who contributed to a study on cardiorenal endpoints in a trial of aliskiren for type 2 diabetes)\n##\n(\"entity\"<|>FERRARIO CM<|>PERSON<|>Ferrario CM is a researcher who contributed to a study on the role of mineralocorticoid receptor antagonists in cardiovascular disease)\n##\n(\"entity\"<|>SCHIFFRIN EL<|>PERSON<|>Schiffrin EL is a researcher who contributed to a study on the role of mineralocorticoid receptor antagonists in cardiovascular disease)\n##\n(\"entity\"<|>CIRCRES<|>ORGANIZATION<|>CircRes is a journal that published a study on the role of mineralocorticoid receptor antagonists in cardiovascular disease in 2015)\n##\n(\"entity\"<|>苏定冯<|>PERSON<|>苏定冯 is a researcher who contributed to a book on cardiovascular pharmacology)\n##\n(\"entity\"<|>陈丰原<|>PERSON<|>陈丰原 is a researcher who contributed to a book on cardiovascular pharmacology)\n##\n(\"entity\"<|>GRUNEJ<|>PERSON<|>GruneJ is a researcher who contributed to a study on selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity)\n##\n(\"entity\"<|>BEYHOFFN<|>PERSON<|>BeyhoffN is a researcher who contributed to a study on selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity)\n##\n(\"entity\"<|>SMEIRE<|>PERSON<|>SmeirE is a researcher who contributed to a study on selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity)\n##\n(\"entity\"<|>HYPERTENSION<|>ORGANIZATION<|>Hypertension is a journal that published a study on selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity in 2018)\n##\n(\"entity\"<|>GOMEZ-SANCHEZEP<|>PERSON<|>Gomez-SanchezEP is a researcher who contributed to a study on third-generation mineralocorticoid receptor antagonists)\n##\n(\"entity\"<|>J CARDIOVASC PHARMACOL<|>ORGANIZATION<|>J Cardiovasc Pharmacol is a journal that published a study on third-generation mineralocorticoid receptor antagonists in 2016)\n##\n(\"entity\"<|>WILLIAMS B<|>PERSON<|>Williams B is a researcher who contributed to a study on spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension)\n##\n(\"entity\"<|>MACDONALD TM<|>PERSON<|>MacDonald TM is a researcher who contributed to a study on spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension)\n##\n(\"entity\"<|>MORANTS<|>PERSON<|>MorantS is a researcher who contributed to a study on spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension)\n##\n(\"relationship\"<|>WANGJG<|>YUKISADAK<|>WangJG and YukisadaK are co-authors of a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension<|>5)\n##\n(\"relationship\"<|>WANGJG<|>SIBULOAJR<|>WangJG and SibuloAJr are co-authors of a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension<|>5)\n##\n(\"relationship\"<|>YUKISADAK<|>SIBULOAJR<|>YukisadaK and SibuloAJr are co-authors of a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension<|>5)\n##\n(\"relationship\"<|>LIW<|>GONG M<|>LiW and Gong M are co-authors of a study on the efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension<|>5)\n##\n(\"relationship\"<|>LIW<|>YU Q<|>LiW and Yu Q are co-authors of a study on the efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension<|>5)\n##\n(\"relationship\"<|>GONG M<|>YU Q<|>Gong M and Yu Q are co-authors of a study on the efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension<|>5)\n##\n(\"relationship\"<|>JACKSON AM<|>JHUNDPS<|>Jackson AM and JhundPS are co-authors of a study on sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction<|>5)\n##\n(\"relationship\"<|>JACKSON AM<|>ANANDIS<|>Jackson AM and AnandIS are co-authors of a study on sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction<|>5)\n##\n(\"relationship\"<|>JHUNDPS<|>ANANDIS<|>JhundPS and AnandIS are co-authors of a study on sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction<|>5)\n##\n(\"relationship\"<|>中国医疗保健国际交流促进会高血压分会<|>中国医师协会心血管分会<|>中国医疗保健国际交流促进会高血压分会 and 中国医师协会心血管分会 are co-authors of a Chinese expert recommendation on the clinical application of sacubitril/valsartan in hypertensive patients<|>5)\n##\n(\"relationship\"<|>中国医疗保健国际交流促进会高血压分会<|>中国高血压联盟<|>中国医疗保健国际交流促进会高血压分会 and 中国高血压联盟 are co-authors of a Chinese expert recommendation on the clinical application of sacubitril/valsartan in hypertensive patients<|>5)\n##\n(\"relationship\"<|>中国医师协会心血管分会<|>中国高血压联盟<|>中国医师协会心血管分会 and 中国高血压联盟 are co-authors of a Chinese expert recommendation on the clinical application of sacubitril/valsartan in hypertensive patients<|>5)\n##\n(\"relationship\"<|>BROWN MJ<|>MCINNES GT<|>Brown MJ and McInnes GT are co-authors of a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control<|>5)\n##\n(\"relationship\"<|>BROWN MJ<|>PAPSTCC<|>Brown MJ and PapstCC are co-authors of a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control<|>5)\n##\n(\"relationship\"<|>MCINNES GT<|>PAPSTCC<|>McInnes GT and PapstCC are co-authors of a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control<|>5)\n##\n(\"relationship\"<|>DUPREZDA<|>MUNGERMA<|>DuprezDA and MungerMA are co-authors of a study on aliskiren for geriatric lowering of systolic hypertension<|>5)\n##\n(\"relationship\"<|>DUPREZDA<|>BOTHAJ<|>DuprezDA and BothaJ are co-authors of a study on aliskiren for geriatric lowering of systolic hypertension<|>5)\n##\n(\"relationship\"<|>MUNGERMA<|>BOTHAJ<|>MungerMA and BothaJ are co-authors of a study on aliskiren for geriatric lowering of systolic hypertension<|>5)\n##\n(\"relationship\"<|>PARVING HH<|>PERSSON F<|>Parving HH and Persson F are co-authors of a study on aliskiren combined with losartan in type 2 diabetes and nephropathy<|>5)\n##\n(\"relationship\"<|>PARVING HH<|>LEWIS JB<|>Parving HH and Lewis JB are co-authors of a study on aliskiren combined with losartan in type 2 diabetes and nephropathy<|>5)\n##\n(\"relationship\"<|>PERSSON F<|>LEWIS JB<|>Pers"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_29daa1b1514e17360fa4c23071fecc229a475b9b68c3da4b0cc59212a483bd23_v2"}